Pegcetacoplan is a self-administered, twice weekly (1080 mg subcutaneous [SC]) infusion and is licensed in Europe for the treatment of adult patients with PNH whose anaemia is uncontrolled after treatment with a C5 inhibitor for ≥ 3 months [11]. The gene discussed is C5; the disease is anemia.